Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

D9302

Sigma-Aldrich

Diacerein

≥95% (HPLC)

Synonym(s):

1,8-Diacetoxy-3-carboxyanthraquinone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H12O8
CAS Number:
13739-02-1
Molecular Weight:
368.29
EC Number:
237-310-2
MDL number:
MFCD00468030
UNSPSC Code:
41116107
PubChem Substance ID:
24894281
NACRES:
NA.25

Quality Level

200

Assay

≥95% (HPLC)

form

powder

SMILES string

CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O

InChI

1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)

InChI key

TYNLGDBUJLVSMA-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Diacerin is an inhibitor of Interleukin-1B (IL-1B) production.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Vinícius Maria Gadotti et al.
Pharmacology, biochemistry, and behavior, 102(4), 549-554 (2012-07-04)
The present study evaluated the antinociceptive effect of the pro-inflammatory cytokines inhibitor diacerein in mice and its possible mechanism of action. The antinociception produced by diacerein was tested at different sites of action, moreover selective antagonists or agonists were used
E M Bartels et al.
Osteoarthritis and cartilage, 18(3), 289-296 (2009-10-28)
To estimate the efficacy and safety of diacerein as a pain-reducing agent in the treatment of osteoarthritis (OA), using meta-analysis of published randomized placebo-controlled trials (RCTs). Systematic searches of the bibliographic databases Medline, Embase, Cinahl, Chemical Abstracts, Cochrane and Web
Pascal Richette
Therapie, 66(5), 383-390 (2011-10-28)
According to international recommendations, acetaminophen should be used as a first-line therapy in patients with osteoarthritis, because of its safety and effectiveness. NSAIDs should be considered in patients unresponsive to acetaminophen, and should be prescribed at the lowest effective dose
Olivier Bruyère et al.
BMC musculoskeletal disorders, 9, 165-165 (2008-12-18)
Symptomatic slow-acting drugs (SYSADOA) have been largely studied over the last decade. The objective of this study is to prepare a document providing recommendations for the use of SYSADOA in osteoarthritis (OA). The following interventions were taken into consideration: avocado/soybean
Amit Kumar Aggarwal et al.
Drug development and industrial pharmacy, 37(10), 1181-1191 (2011-04-01)
Diacerein (DCN) is a new anti-inflammatory analgesic and antipyretic drug developed specially for the treatment of osteoarthritis. DCN is a poorly water-soluble drug with relatively low bioavailability. Therefore, the purpose of this study was to enhance the solubility and dissolution
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service